Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT02567149
Other study ID # Version 1.0
Secondary ID
Status Withdrawn
Phase Phase 2
First received September 30, 2015
Last updated June 28, 2017
Start date June 2016
Est. completion date June 2016

Study information

Verified date June 2017
Source University of Minnesota - Clinical and Translational Science Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to determine whether intralesional cidofovir is effective at bringing about the total or near-total resolution of warts that have already proven recalcitrant to standard therapy.

The secondary objective is to determine the tolerability of this new mode of administration of cidofovir in the pediatric population


Description:

This study includes pediatric patients with history of either primary or iatrogenic immune-suppression who are seeking treatment of warts that have already proven recalcitrant to standard therapy. The first cohort will include 4 patients ages 12 to 17. After all tests indicate treatment safety, the second cohort will be recruited and will include patients ages 8 to 17.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date June 2016
Est. primary completion date June 2016
Accepts healthy volunteers No
Gender All
Age group 12 Years to 17 Years
Eligibility Inclusion Criteria:

- 1. The first cohort will include a total of 4 patients ages 12 to 17. After all tests indicate treatment safety, the second cohort will be recruited and will include patients ages 8 to 17.Patient is in immune-suppressed status by one of the following:

1. Primary immunodeficiency, which may include but is not limited to the following:

1. Chronic Granulomatous Disease (CGD)

2. Common Variable Immunodeficiency (CVID)

3. DiGeorge Syndrome (DGS)

4. Selective IgA Deficiency

5. Severe Combined Immunodeficiency (SCID)

6. X-Linked Agammaglobulinemia (XLA)

2. Pharmacologic immune-suppressed status from medications including but not limited to:

1. prednisone

2. cyclosporine

3. azathioprine

4. tacrolimus/ FK506

5. mycophenolate mofetil

6. sirolimus

2. Patient has history of clinically-significant warts that are either refractory to standard therapy or for which standard therapy is contra-indicated or unreasonable 3. Patient has a total wart burden of at least 1cm 4. Patients must have tried and failed at least 2 other conventional treatments for cutaneous warts, including but not limited to:

- cryotherapy

- topical salicylic acid

- imiquimod

- topical 5FU

- pulsed dye laser therapy

- sinecatechins

- tretinoin or other topical retinoid

- intralesional candida injection

- bleomycin

- electrocautery

- topical cidofovir cream or gel

There will be a one month washout period for all treatment modalities, with the exception of intralesional candida, which will be 3 months.

5. Patient desires ongoing treatment of their warts 6. Patient and/or their parent/guardian consents to participating in this study

Exclusion Criteria:

1. Treatment area is either ulcerated, secondarily infected, or significantly inflamed

2. Treatment area is on face or groin area

3. Patient is pregnant, attempting to become pregnant, or lactating

4. Patient reports active kidney disease, or chart review reveals recent serum creatinine =1.5mg/dL or a history of renal disease/insufficiency or history of diabetes

5. Patient is currently receiving a nephrotoxic medication

6. Patient has history of hypersensitivity to cidofovir

7. Patient is severely ill and/or hospitalized

8. Patient is receiving chemotherapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cidofovir
Cidofovir

Locations

Country Name City State
United States University of Minnesota Medical Center Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
University of Minnesota - Clinical and Translational Science Institute

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical resolution of treated warts as evaluated by the investigators Total or near-total clinical resolution of treated warts as evaluated by the investigators 6 months
Primary Improvement of wart-associated symptoms 2. Patient-perceived improvement of wart-associated symptoms 6 months
Secondary Patient/parent reported tolerability of the treatment 6 months
See also
  Status Clinical Trial Phase
Completed NCT01757392 - Candin Safety & Efficacy Study for the Treatment of Warts Phase 2
Completed NCT00973856 - Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands N/A
Completed NCT02902822 - Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo N/A
Withdrawn NCT00546611 - The Purpose of This Study is to Determine Whether Topical Application of PEP005 is Safe for the Treatment of Common Wart(s) Phase 1
Completed NCT00117871 - Study With a Topical Gel to Treat Common Warts in Adults Phase 2
Completed NCT04278573 - Intralesional Vitamin D Injection for Treatment of Common Warts Phase 2
Completed NCT02231879 - Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome Phase 2/Phase 3
Completed NCT06309420 - Clinical Trial to Evaluate Efficacy and Safety of a Cryogenic Medical Device for Treatment of Common and Plantar Warts N/A
Not yet recruiting NCT05617950 - Salicylic Acid Versus Cryotherapy for the Treatment of HPV1-induced Plantar Warts N/A
Not yet recruiting NCT05616078 - Laser Versus Cryotherapy for the Treatment of Recalcitrant Warts N/A
Recruiting NCT01712295 - 17% Salicylate Versus 17% Salicylate-Ethyl Pyruvate for Plantar Foot Warts Phase 4
Active, not recruiting NCT00254280 - Treatment of Recalcitrant Hand and Foot Warts With Intense Pulsed Light - a Randomized Controlled Trial N/A
Completed NCT04781244 - Cost-effectiveness of EndWarts® FREEZE - an Alternative Home Cryotherapy Device for Wart Treatment N/A
Completed NCT01101750 - Does the HPV Vaccine Cause the Same Response in Adolescent Kidney and Liver Transplant Patients as in Healthy Controls? Phase 4
Completed NCT03487549 - Cantharidin and Occlusion in Verruca Epithelium Phase 2
Recruiting NCT05625633 - Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts Phase 2/Phase 3
Completed NCT02393417 - Safety and Efficacy of Varying Regimens of CANDIN for Treatment of Common Warts (Verruca Vulgaris) Phase 2
Completed NCT01808443 - Efficacy of Laser Versus Cryotherapy in the Treatment of Warts N/A
Completed NCT00116675 - Four Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2
Completed NCT00116662 - An up to Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Pediatric Subjects Phase 2